Altimmune
ALT
109 hedge funds and large institutions have $269M invested in Altimmune in 2021 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 29 increasing their positions, 21 reducing their positions, and 30 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
40% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 30
38% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 21
12% more funds holding
Funds holding: 97 → 109 (+12)
6.86% more ownership
Funds ownership: 64.14% → 71% (+6.9%)
7% less call options, than puts
Call options by funds: $8.26M | Put options by funds: $8.93M
20% less capital invested
Capital invested by funds: $337M → $269M (-$67.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$21.4M |
| 2 |
BlackRock
New York
|
+$20.5M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$12.7M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$10.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$23.1M |
| 2 |
CCM
CAAS Capital Management
New York
|
-$15.6M |
| 3 |
Millennium Management
New York
|
-$10M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$9.73M |
| 5 |
AC
Armistice Capital
New York
|
-$7.57M |
ALT Hedge Fund Activity: Q2 2021 in Review
109 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q2 2021, worth a combined $269M — down 20% from $337M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new ALT positions and 30 closed out — a net gain of 12 holders — while 29 added to existing stakes and 21 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $21.4M. The largest seller was Baker Bros. Advisors, cutting an estimated $23.1M.
- 109 institutional investors held Altimmune (ALT) as of Q2 2021, up from 97 in Q1 2021.
- Funds reported $269M of Altimmune stock for Q2 2021, down 20% quarter-over-quarter.
- 42 funds opened new Altimmune positions in Q2 2021 and 30 closed out, a net change of +12 holders.
- The largest Altimmune buyer in Q2 2021 was Point72 Asset Management, an estimated $21.4M added.
- The largest Altimmune seller in Q2 2021 was Baker Bros. Advisors, an estimated $23.1M sold.
Based on aggregated 13F filings for Q2 2021.